CN101385820B - Traditional Chinese medicine composition containing ephedra for treating dermatomyositis and preparation thereof - Google Patents

Traditional Chinese medicine composition containing ephedra for treating dermatomyositis and preparation thereof Download PDF

Info

Publication number
CN101385820B
CN101385820B CN2007101454105A CN200710145410A CN101385820B CN 101385820 B CN101385820 B CN 101385820B CN 2007101454105 A CN2007101454105 A CN 2007101454105A CN 200710145410 A CN200710145410 A CN 200710145410A CN 101385820 B CN101385820 B CN 101385820B
Authority
CN
China
Prior art keywords
medicine composition
chinese medicine
dermatomyositis
herba
ramulus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2007101454105A
Other languages
Chinese (zh)
Other versions
CN101385820A (en
Inventor
陆春玲
王超
郑立发
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hebei Yiling Pharmaceutical Research Institute Co Ltd
Original Assignee
Hebei Yiling Pharmaceutical Research Institute Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hebei Yiling Pharmaceutical Research Institute Co Ltd filed Critical Hebei Yiling Pharmaceutical Research Institute Co Ltd
Priority to CN2007101454105A priority Critical patent/CN101385820B/en
Publication of CN101385820A publication Critical patent/CN101385820A/en
Application granted granted Critical
Publication of CN101385820B publication Critical patent/CN101385820B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention provides a traditional Chinese medicine composition which contains Chinese ephedra and is used for treating dermatomyositis and a preparation thereof. The dermatomyositis is classified as 'flaccidity syndrome' by the theory of collateral diseases of the Chinese traditional medicine, and the pathogenesis of the dermatomyositis is mainly the deficiency of the spleen and the kidney, no source for the production and transformation of qi and blood, inability of the weakened body resistance to conquer pathogen, and obstruction of the collaterals of muscles and skin by wind cold dampness, thus affecting the liver, the kidney and the spleen and causing the yin collaterals stasis of internal organs, qi-blood disharmony, and malnutrition of the limbs, skin, tendons and channels. Aiming at treating syndromes of collaterals obstruction due to cold and dampness, and dysphagia and blood stasis caused by the dermatomyositis, the traditional Chinese medicine composition determines the treatment based on differentiation of symptoms and signs by using the theory of the collateral diseases of Chinese traditional medicine, and is made from the Chinese ephedra, astragalus root, asarum, Chinese yam, preparation, white mustard seed, pangolin, leatherleaf milletia, winged euony twigs, cassia twig and garter snake to warm yang and expel cold and activate blood circulation for removing obstruction in the channels. Clinical studies prove that the traditional Chinese medicine composition can treat the dermatomyositis effectively.

Description

A kind of Chinese medicine composition and preparation thereof that contains the treatment dermatomyositis of Herba Ephedrae
Technical field
The present invention relates to a kind of Chinese medicine composition and preparation thereof that contains the treatment dermatomyositis of Herba Ephedrae, belong to the Chinese herbal and crude drugs preparations technical field.
Background technology
Dermatomyositis (dermatomyositis, DM) be a kind of striped muscle that mainly involves, apyetous inflammatory myopathy based on lymphocytic infiltration, belong to one of autoimmunity connective tissue disease, the primary disease course of disease is long, the disability rate height is difficult to radical cure, and doctor trained in Western medicine is mainly used glucocorticoid and immunosuppressant treatment.The traditional Chinese medical science is classified as primary disease characteristic symptom and the major lesions mechanism that " myopathy " more meets primary disease.
The dermatomyositis pathogenesis is mainly deficiency of spleen and stomach, and no resource of generating and transforming QI and blood weakened body resistancely can not be driven heresy, and wind and cold is damp and hot to accumulate the network that hinders skin, and then influences the Liver and kidney spleen, causes the internal organs yin collaterals stasis of blood and stagnates, and is qi-blood disharmony, and limbs skin muscle arteries and veins loses supports.The primary disease exopathogen is based on wet, and dampneee being viscous and lingering easily checks mechanism of qi, the humidity hysteresis stagnation of QI, muscle skin meridians impatency is obstructed, its form of expression can have difference, the wet or heat of holding concurrently, or the damp and hot poison that accumulates, or cold-damp go in heat-transformation; Interior-deficiency head blames in the spleen kidney, sees with the deficiency of YIN more, or is the natural endowment deficiency, and cloudy liquid is plain to be lost, or the labor desire is excessively, the smart damage of cloudy consumption, or diseases caused by exogenous pathogenic factor are damp and hot, consumption impairment of QI the moon.The course of disease with the passing of time, deficiency of YIN affecting YANG can be seen syndrome of yang deficiency of spleen and kidney again and wait; No matter invade in the exopathogen, it is puckery still to seek the deficiency of YIN, and no matter sick pathogenic heat noxious dampness is just violated network, still pathogen usually intruding into collateral in protracted disease, and venation is a basic pathology mechanism of dermatomyositis for disease, also is to cause primary disease to show effect repeatedly, delays the principal element that difficulty heals.The clinical manifestation of dermatomyositis: muscle weakness, involve extremity more, can involve cervical region and oblongata myasthenia, even muscle weakness can appear breathing in severe patient; Can accompany skin turgor, or erythema or erythema; Part patient's myalgia.The limb muscle atrophy can appear in late period, and tendon reflex disappears, and severe patient can cause pulmonary fibrosis or paralysis of respiratory muscle death.
Cold-damp resistance network, air bound blood gathers the type dermatomyositis, and its clinical manifestation is: skin turgor, macule is dark red, whole body myalgia, weakness, coldness of the body with chills, heavy sensation of the body is tired, course of disease delay, light red tongue, tongue is white, deep-slow pulse or heavy thin.Its former because: the heresy of cold-damp is gone into from the flesh table, defends gas to be held back, and the meridians impatency is obstructed, so see myalgia; Cold Sheng is then swollen, and so the damp of holding concurrently again is skin turgor; Cold having the property of coagulation, blood vessels are not smooth, so see that the speckle color is dark red; A little less than the deficiency of YANG QI, can not be warm, so coldness of the body with chills, heavy sensation of the body are tired; Light red tongue, tongue is white, deep-slow pulse or heavy thin resembling for the cold Sheng of yang deficiency.
Modern medicine is used glucocorticoid, immunoglobulin, immunosuppressant and multivitamin treatment more at present, and wherein glucocorticoid is most widely used general, and is cheap.But the glucocorticoid effect lacks specificity, and life-time service produces various untoward reaction to human body.Tradition Chinese medicine dermatomyositis is also had nothing in common with each other, and the rule of treatment differs.
Summary of the invention
The invention provides a kind of Chinese medicine composition and preparation thereof that contains the treatment dermatomyositis of Herba Ephedrae.The common pathogenesis of venation pathological changes of dermatomyositis is that the QI and blood or the resistance of seminal fluid numbness of channels is obstructed, so collateral dredging is total Therapeutic Principle.
Chinese medicine composition of the present invention is selected Herba Ephedrae, Herba Asari, Radix Aconiti, Ramulus Cinnamomi acrid in the mouth active, the dispelling cold and removing dampness that activates yang for use; The Radix Astragali, Rhizoma Dioscoreae benefiting QI for strengthening the superficies, invigorating the spleen for eliminating dampness; Semen Sinapis Albae, Squama Manis, Caulis Spatholobi, Ramulus Euonymi, Zaocys collateral dredging are searched heresy.
The invention provides a kind of Chinese medicine composition that contains the treatment dermatomyositis of Herba Ephedrae, it is characterized in that being making by the crude drug of following weight portion ratio:
Herba Ephedrae 6-12 Radix Astragali 9-45 Herba Asari 3-9 Rhizoma Dioscoreae 15-30
Radix Aconiti 3-6 Semen Sinapis Albae 6-15 Squama Manis 6-18 Caulis Spatholobi 9-30
Ramulus Euonymi 9-30 Ramulus Cinnamomi 9-18 Zaocys 12-20
Preferably, Chinese medicine composition of the present invention is to be made by the crude drug of following weight portion ratio:
Herba Ephedrae 6-12 Radix Astragali 15-35 Herba Asari 3-9 Rhizoma Dioscoreae 15-25
Radix Aconiti 3-6 Semen Sinapis Albae 6-15 Squama Manis 6-18 Caulis Spatholobi 15-20
Ramulus Euonymi 15-20 Ramulus Cinnamomi 9-18 Zaocys 12-20
More preferably, Chinese medicine composition of the present invention is to be made by the crude drug of following weight portion ratio:
Herba Ephedrae 9 Radixs Astragali 25 Herba Asaris 6.5 Rhizoma Dioscoreaes 21
Radix Aconiti 4.5 Semen Sinapis Albaes 10 Squama Maniss 11 Caulis Spatholobis 19.5
Ramulus Euonymi 19.5 Ramulus Cinnamomi 12 Zaocyss 15
Or make by the crude drug of following weight portion ratio:
Herba Ephedrae 6 Radixs Astragali 45 Herba Asaris 3 Rhizoma Dioscoreaes 30
Radix Aconiti 3 Semen Sinapis Albaes 15 Squama Maniss 6 Caulis Spatholobis 30
Ramulus Euonymi 9 Ramulus Cinnamomi 18 Zaocyss 20
Or make by the crude drug of following weight portion ratio:
Herba Ephedrae 11 Radixs Astragali 12 Herba Asaris 8 Rhizoma Dioscoreaes 20
Radix Aconiti 4.5 Semen Sinapis Albaes 14 Squama Maniss 7.5 Caulis Spatholobis 27
Ramulus Euonymi 27 Ramulus Cinnamomi 12 Zaocyss 18
Or make by the crude drug of following weight portion ratio:
Herba Ephedrae 7 Radixs Astragali 35 Herba Asaris 4 Rhizoma Dioscoreaes 25
Radix Aconiti 4.5 Semen Sinapis Albaes 8.5 Squama Maniss 16 Caulis Spatholobis 15
Ramulus Euonymi 25 Ramulus Cinnamomi 16 Zaocyss 14
The preparation formulation of Chinese medicine composition of the present invention is decoction, powder, capsule, tablet, pill or oral liquid.
The dosage form of Chinese medicine composition of the present invention adopts conventional preparation method preparation, and for example, the preparation technology of Fan Biting " pharmacy of Chinese materia medica " (Shanghai Science Press 1997 December the 1st edition) record makes the acceptable regular dosage form of pharmaceutics.
In the application of the present invention, described Chinese medicine composition is a kind of in decoction, powder, capsule, tablet, pill, the oral liquid formulations, for above-mentioned dosage form can be realized, need when these dosage forms of preparation, to add the pharmacy acceptable auxiliary, for example: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic, substrate etc.Filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc.; Disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc.; Lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc.; Suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc.; Binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc.; Sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc.; Correctives comprises: sweeting agent and various essence; Antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, fixed, the Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods of acetic acid chloroethene; Substrate comprises: PEG6000, PEG4000, insect wax etc.For making above-mentioned dosage form can realize pharmacy of Chinese materia medica, need when these dosage forms of preparation, to add acceptable other adjuvant of pharmacy (adjuvant of each dosage form record among the Fan Biting " pharmacy of Chinese materia medica ", Shanghai Science Press December in 1997 the 1st edition).
Preferably, the dermatomyositis of traditional Chinese medicine composition for treating of the present invention is cold-damp resistance network, the poly-type dermatomyositis of air bound blood.We are because of warming YANG to expel cold, and promoting blood circulation to remove obstruction in the collateral so the treatment cold-damp hinders network, the poly-type dermatomyositis of air bound blood, has better effect.
Be confirmation clinical drug curative effect of the present invention, the decoction that use prepares according to embodiment 1 described method (to call in the following text: medicine of the present invention) carried out following clinical observation:
One, clinical diagnosis standard
Standard formulation with reference to propositions in 1975 such as Bohan
1, main standard:
A, typical dermatosis (the purplish red erythra of eyelid), peripheral vessel expansion and finger are stretched side squama erythema or extremity trunk erythema.
B, muscular strength reduce flesh tenderness and scleroma, slow movement and the obvious amyotrophy of extremity peri position.
Inflammatory cell infiltration, edema are seen in c, flesh biopsy, muscle fiber hyalinosis or cavity necrosis, and the muscle fiber thickness differs, interstitial fibrosis, muscle fiber orthogenesis etc.
D, sero-enzyme GOT, GPT, LDH, aldolase etc. surpass normal value 5%.
The existing of e, electromyography showed myositis (use 17-hydroxy-11-dehydrocorticosterone or spasmolytic etc. and then can influence positive findings).
2, minor criteria
A, calcific deposit.
B, dysphagia.
3, diagnositc decision
Possess 3 in 5 of the main standard, or 2 of main standard add 2 of minor criterias, promptly be diagnosed as dermatomyositis (skin symptom is not polymyositis for a long time).
Main standard have only 1 and (or) 2 times, then possess 1 of 2 of main standard or main standard and add 2 of minor criterias and promptly be diagnosed as dermatomyositis.
Special-shaped: with the polymyositis or the dermatomyositis of malignant tumor.
Except: struvite muscle illness or dermatomyositis that reason is clear and definite.
4, traditional Chinese medical science disease diagnostic criteria:
Cold-damp resistance network, air bound blood gathers type:
Primary symptom: (1) limb muscle atrophy is unable, (2) skin turgor or erythema (3) myalgia.
Inferior disease: (1) pale tongue is dark, and tongue is white, (2) deep-slow pulse or heavy thin;
(3) heavy sensation of the body is tired, and coldness of the body with chills (4) macule is dark red, state of an illness delay.
Two of above primary symptoms or more than add two of time diseases or more than be diagnosed as this type.
Two, data and method
1, physical data:
This research is carried out in Hebei Yi Ling hospital, and all cases meet above-mentioned doctor trained in Western medicine criterion.Age excludes this research greater than 65 years old and the organ injury persons such as severe cardiac, liver, kidney (in the inpatient therapeutic process send out survivor except) of occurring together.Medicine group 117 examples of the present invention are inpatient; Male's 22 examples wherein, women's 95 examples; 14~60 years old age, average 45 years old; The course of disease is smaller or equal to 1 year person's 18 example, 1~3 year person's 47 example, and 4~7 years person's 43 examples, more than or equal to 8 years person's 9 examples, wherein 53 examples met cold-damp resistance network, the traditional Chinese medical science disease diagnostic criteria of the poly-type of air bound blood.Matched group 46 examples also are inpatient; Male's 10 examples wherein, women's 36 examples; 17~62 years old age, average 40 years old; The course of disease is smaller or equal to 1 year person's 9 example, 1~3 year person's 17 example, and 4~7 years person's 18 examples, more than or equal to 8 years person's 2 examples, wherein 22 examples met traditional Chinese medical science cold-damp resistance network, the traditional Chinese medical science disease diagnostic criteria of the poly-type of air bound blood.Treat preceding two groups of patients at aspect difference not statistically significants such as sex, age, the course of disease, degree of being in a bad way.
2, Therapeutic Method:
2.1 medicine group of the present invention: take medicine of the present invention, 600 milliliters of every days, divide twice decoction being taken warmly sooner or later.Glucocorticoid treatment: prednisone 0.8-1.5 mg/day/kilogram.To wherein meet cold-damp resistance network, the poly-type traditional Chinese medical science disease diagnostic criteria of air bound blood be divided into the S1 subgroup, all the other do not meet cold-damp resistance network, the traditional Chinese medical science disease diagnostic criteria of the poly-type of air bound blood be divided into the S2 subgroup, above-mentioned two hypotypes all adopt identical treatment measure.
2.2 matched group: give merely and glucocorticoid treatment, consumption is the same.
3, be 3 months the course of treatment course of treatment.
4, observation index: deflorescence situation, muscular strength, creatine phosphokinase.That observes untoward reaction, relapse rate and hormone simultaneously removes the situation of subtracting smoothly.The muscular strength grade scale is with reference to the grade scale of Britain Medical Res Council.
5, curative effect determinate standard: " the new Chinese medicine clinical research guideline (dermatomyositis) " of Ministry of Public Health promulgation formulated with reference to nineteen ninety-five.
The clinical recovery standard: erythra disappears fully, and the muscle Myodynamia recovery is normal, and it is normal that myocardium enzyme is recovered.
Clinical produce effects standard: the erythra major part disappears, and the muscle muscular strength increases the 2-3 level, and 2 or above measured value descend and surpass 50% in the myocardium enzyme.
Clinical effective standard: erythra partly disappears, and the muscle muscular strength increases the 1-2 level, and myocardium enzyme has 2 or above decline 25-50%.
Clinical invalid standard: erythra does not have minimizing, and muscular strength increases by 1 grade of less than, the myocardium enzyme equal less than 25% that descends.
6, statistical method
Two groups of curative effects relatively adopt rank test, and total effective rate relatively adopts X 2 test.Adopt the SPSS10.0 statistical software, there is statistical significance P<0.05 for difference; Two subgroup curative effects more also adopt rank test, and there is statistical significance P<0.05 for difference;
Three, result
1, medication therapy groups of the present invention and matched group curative effect are relatively
Table 1 liang group clinical curative effect analysis (routine number, %)
Grouping The example number Recovery from illness Produce effects Effectively Invalid Total effective rate (%)
Medicine group of the present invention 117 ?7(6.0) 49(41.9) 42(35.9) 19(16.2) 83.8
Matched group 44 ?2(2.2) 12(30.4) 14(34.8) 16(32.6) 67.4
Two groups of general curative effects relatively adopt rank test, p=0.014, so medicine group of the present invention and matched group have marked difference on general curative effect, and the matched group that is better than evident in efficacy of medicine of the present invention; Two groups of total effective rates relatively adopt X 2 test, p=0.021, so there were significant differences on total effective rate in matched group for medicine group of the present invention, the effective percentage of medicine of the present invention is significantly higher than matched group.
2, different TCM Syndrome Type curative effects relatively
The different TCM Syndrome Type efficacy analysis of table 2 (routine number, %)
Grouping The example number Recovery from illness Produce effects Effectively Invalid Total effective rate (%)
The S1 group 53 ?5(9.4) 25(47.2) 19(35.8) 4(7.5) 92.45
The S2 group 64 ?2(3.1) 26(37.5) 23(35.9) 15(23.4) 76.56
Two groups of general curative effects relatively adopt rank test, p=0.019, so S1 group has marked difference with the S2 group on general curative effect, medicine of the present invention hinders network for cold-damp, and the poly-type dermatomyositis of air bound blood evident in efficacy is better than non-cold-damp resistance network, and air bound blood gathers the type dermatomyositis.
Four, conclusion
Chinese medicine composition of the present invention can effectively be treated dermatomyositis, treatment cold-damp resistance network, and air bound blood gathers the type dermatomyositis, has better effect.
The specific embodiment
Example below in conjunction with the preparation of medicine decoction of the present invention, powder, capsule, tablet, pill, oral liquid illustrates the specific embodiment of the present invention.
Embodiment 1:
The Herba Ephedrae 9 gram Radixs Astragali 25 gram Herba Asaris 6.5 Keshan medicines 21 grams
Radix Aconiti 4.5 gram Semen Sinapis Albaes 10 gram Squama Maniss 11 gram Caulis Spatholobis 19.5 grams
Ramulus Euonymi 19.5 gram Ramulus Cinnamomi 12 gram Zaocyss 15 grams
Preparation method: the above-mentioned raw materials medicine, add clear water and soak half an hour for 1 liter, intense fire decocts to boiling, continue slow fire boiling half an hour, filter 300 milliliters of extracting juice, repeat again to decoct once, filter, 300 milliliters of extracting juice merge the medicine juice of twice decoction, mixing, amount to 600 milliliters, promptly get decoction, divide twice decoction being taken warmly sooner or later.
Embodiment 2:
The Herba Ephedrae 6 gram Radixs Astragali 45 gram Herba Asaris 3 Keshan medicines 30 grams
Radix Aconiti 3 gram Semen Sinapis Albaes 15 gram Squama Maniss 6 gram Caulis Spatholobis 30 grams
Ramulus Euonymi 9 gram Ramulus Cinnamomi 18 gram Zaocyss 20 grams
Preparation method: formulation method is total to the porphyrize foam routinely, makes powder.
Embodiment 3:
The Herba Ephedrae 11 gram Radixs Astragali 12 gram Herba Asaris 8 Keshan medicines 20 grams
Radix Aconiti 4.5 gram Semen Sinapis Albaes 14 gram Squama Maniss 7.5 gram Caulis Spatholobis 27 grams
Ramulus Euonymi 27 gram Ramulus Cinnamomi 12 gram Zaocyss 18 grams
Preparation method: formulation method is made capsule routinely.
Embodiment 4:
The Herba Ephedrae 7 gram Radixs Astragali 35 gram Herba Asaris 4 Keshan medicines 25 grams
Radix Aconiti 4.5 gram Semen Sinapis Albaes 8.5 gram Squama Maniss 16 gram Caulis Spatholobis 15 grams
Ramulus Euonymi 25 gram Ramulus Cinnamomi 16 gram Zaocyss 14 grams
Preparation method: formulation method is made tablet routinely.
Embodiment 5:
The Herba Ephedrae 8 gram Radixs Astragali 30 gram Herba Asaris 5 Keshan medicines 20 grams
Radix Aconiti 5.5 gram Semen Sinapis Albaes 7 gram Squama Maniss 16 gram Caulis Spatholobis 17 grams
Ramulus Euonymi 17 gram Ramulus Cinnamomi 15.5 gram Zaocyss 14 grams
Preparation method: formulation method is made pill routinely.
Embodiment 6:
The Herba Ephedrae 9 gram Radixs Astragali 11 gram Herba Asaris 7 Keshan medicines 17 grams
Radix Aconiti 3.5 gram Semen Sinapis Albaes 11 gram Squama Maniss 15.5 gram Caulis Spatholobis 22 grams
Ramulus Euonymi 28 gram Ramulus Cinnamomi 10.5 gram Zaocyss 16.5 grams
Preparation method: formulation method is made oral liquid routinely.

Claims (9)

1. Chinese medicine composition that contains the treatment dermatomyositis of Herba Ephedrae is characterized in that being being made by the crude drug of following weight portion ratio:
Herba Ephedrae 6-12 Radix Astragali 9-45 Herba Asari 3-9 Rhizoma Dioscoreae 15-30
Radix Aconiti 3-6 Semen Sinapis Albae 6-15 Squama Manis 6-18 Caulis Spatholobi 9-30
Ramulus Euonymi 9-30 Ramulus Cinnamomi 9-18 Zaocys 12-20
2. Chinese medicine composition according to claim 1 is characterized in that being being made by the crude drug of following weight portion ratio:
Herba Ephedrae 6-12 Radix Astragali 15-35 Herba Asari 3-9 Rhizoma Dioscoreae 15-25
Radix Aconiti 3-6 Semen Sinapis Albae 6-15 Squama Manis 6-18 Caulis Spatholobi 15-20
Ramulus Euonymi 15-20 Ramulus Cinnamomi 9-18 Zaocys 12-20
3. Chinese medicine composition according to claim 1 is characterized in that being being made by the crude drug of following weight portion ratio:
Herba Ephedrae 9 Radixs Astragali 25 Herba Asaris 6.5 Rhizoma Dioscoreaes 21
Radix Aconiti 4.5 Semen Sinapis Albaes 10 Squama Maniss 11 Caulis Spatholobis 19.5
Ramulus Euonymi 19.5 Ramulus Cinnamomi 12 Zaocyss 15
4. Chinese medicine composition according to claim 1 is characterized in that being being made by the crude drug of following weight portion ratio:
Herba Ephedrae 6 Radixs Astragali 45 Herba Asaris 3 Rhizoma Dioscoreaes 30
Radix Aconiti 3 Semen Sinapis Albaes 15 Squama Maniss 6 Caulis Spatholobis 30
Ramulus Euonymi 9 Ramulus Cinnamomi 18 Zaocyss 20
5. Chinese medicine composition according to claim 1 is characterized in that being being made by the crude drug of following weight portion ratio:
Herba Ephedrae 11 Radixs Astragali 12 Herba Asaris 8 Rhizoma Dioscoreaes 20
Radix Aconiti 4.5 Semen Sinapis Albaes 14 Squama Maniss 7.5 Caulis Spatholobis 27
Ramulus Euonymi 27 Ramulus Cinnamomi 12 Zaocyss 18
6. Chinese medicine composition according to claim 1 is characterized in that being being made by the crude drug of following weight portion ratio:
Herba Ephedrae 7 Radixs Astragali 35 Herba Asaris 4 Rhizoma Dioscoreaes 25
Radix Aconiti 4.5 Semen Sinapis Albaes 8.5 Squama Maniss 16 Caulis Spatholobis 15
Ramulus Euonymi 25 Ramulus Cinnamomi 16 Zaocyss 14
7. according to the arbitrary described Chinese medicine composition of claim 1-6, the preparation formulation that it is characterized in that this Chinese medicine composition is decoction, powder, capsule, tablet, pill or oral liquid.
8. Chinese medicine composition as claimed in claim 7 is characterized in that decoction, powder, capsule, tablet, pill or the oral liquid of this Chinese medicine composition contains one or more pharmaceutically acceptable excipient.
9. hinder network according to the arbitrary described Chinese medicine composition of claim 1-6 in preparation treatment cold-damp, the application in the poly-type dermatomyositis medicine of air bound blood.
CN2007101454105A 2007-09-11 2007-09-11 Traditional Chinese medicine composition containing ephedra for treating dermatomyositis and preparation thereof Active CN101385820B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2007101454105A CN101385820B (en) 2007-09-11 2007-09-11 Traditional Chinese medicine composition containing ephedra for treating dermatomyositis and preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2007101454105A CN101385820B (en) 2007-09-11 2007-09-11 Traditional Chinese medicine composition containing ephedra for treating dermatomyositis and preparation thereof

Publications (2)

Publication Number Publication Date
CN101385820A CN101385820A (en) 2009-03-18
CN101385820B true CN101385820B (en) 2010-12-22

Family

ID=40475626

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007101454105A Active CN101385820B (en) 2007-09-11 2007-09-11 Traditional Chinese medicine composition containing ephedra for treating dermatomyositis and preparation thereof

Country Status (1)

Country Link
CN (1) CN101385820B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1231187A (en) * 1998-04-04 1999-10-13 周正平 Traditional Chinese medicine preparation for curing arthralgia due to windcold-dampness
CN1408379A (en) * 2001-09-30 2003-04-09 刘武汉 Notoginseng and pangolin scales tinea curing pill

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1231187A (en) * 1998-04-04 1999-10-13 周正平 Traditional Chinese medicine preparation for curing arthralgia due to windcold-dampness
CN1408379A (en) * 2001-09-30 2003-04-09 刘武汉 Notoginseng and pangolin scales tinea curing pill

Also Published As

Publication number Publication date
CN101385820A (en) 2009-03-18

Similar Documents

Publication Publication Date Title
CN102357187B (en) Traditional Chinese medicine composition for treating acute lumbar sprain
CN102441081B (en) Medicament for treating gout and its preparation method
CN102188685B (en) Externally-applied traditional Chinese medicine powder for treating diarrhea type irritable bowel syndrome and preparation method thereof
CN101254286B (en) Chinese medicinal composition for curing wind dampness and rheumatoid
CN103041145B (en) Traditional Chinese medicine composition for treating exogenous fever
CN104547736A (en) Medicine for treating goiter
CN104147194A (en) Traditional Chinese medicine composition for treating chronic sinusitis
CN101036717A (en) Orally taken type Chinese traditional medicine combination for curing irritable bowel syndrome
CN101385812B (en) Traditional Chinese medicine composition containing epimeddium for treating dermatomyositis and preparation thereof
CN101385805B (en) Traditional Chinese medicine composition containing cicada-shell for treating dermatomyositis and preparation thereof
CN101385836B (en) Traditional Chinese medicine composition containing poria cocos for treating dermatomyositis and preparation thereof
CN101385810B (en) Traditional Chinese medicine composition containing chinemys reevesii for treating dermatomyositis and preparation thereof
CN101385820B (en) Traditional Chinese medicine composition containing ephedra for treating dermatomyositis and preparation thereof
CN102579895B (en) Traditional Chinese medicine composition for treating psoriasis
CN101502583A (en) Chinese medicament preparation for treating cholecystitis and gall-stone as well as preparation method thereof
CN105381260A (en) Traditional Chinese medicine for treating acquired immune deficiency syndrome and preparation method thereof
CN102552824B (en) Traditional Chinese medicine prepared prescription for treating psoriasis
CN102335304B (en) Chinese medicine composition for dispelling wind, removing dampness, invigorating blood circulation, and relieving pain and preparation method thereof
CN102764325B (en) Chinese medicinal composition for dispelling rheumatism and relieving pain
CN105770520A (en) Medicine preparation used for treating coronary heart disease and application thereof
CN104998106A (en) Traditional Chinese medicine composition for treating allergic rhinitis
CN105726849B (en) It is a kind of for treating the Chinese medicine of diabetes Depression
CN104274702A (en) Traditional Chinese medicine preparation for treating chronic cardiac-failure qi deficiency and blood stasis and syndrome of internal stagnation of fluid-dampness
CN103830679A (en) Medicine for treating irritable bowel syndrome and applications thereof
CN104147137B (en) A kind of medicament for the treatment of infertility

Legal Events

Date Code Title Description
PB01 Publication
C06 Publication
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
GR01 Patent grant
C14 Grant of patent or utility model